Isoglipt-M 50/500 Tablet is a combination oral antihyperglycemic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby promoting insulin release and suppressing glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The combination therapy targets multiple pathophysiological defects in type 2 diabetes, providing improved glycemic control compared to monotherapy. Isoglipt-M 50/500 is typically prescribed when diet, exercise, and monotherapy with either agent do not achieve adequate glycemic control. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while rare but serious risks include lactic acidosis and pancreatitis. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Isoglipt-M 50/500 Tablet should be used as part of a comprehensive diabetes management plan including lifestyle modifications.